New study from Maverex on the risk of stroke and myocardial infarction in systemic lupus erythematosus patients

 

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis developed with our partners at AstraZeneca, is a systematic review of the risk of stroke and myocardial infarction (MI) in adult patients with systemic lupus erythematosus (SLE), a chronic autoimmune disorder associated with increased comorbidities. Epidemiological studies have suggested that patients with SLE have an increased risk of cardiovascular events.

This is the first meta-analysis to assess the risk of both stroke and MI across multiple observational study types in adult patients with SLE compared with the general population or healthy controls. We found that the pooled relative risk of stroke (intracerebral haemorrhage, ischaemic stroke and subarachnoid haemorrhage) and MI from 26 observational studies was found to be twofold to threefold higher among patients with SLE compared with the general population or healthy controls.

You can read the article in full on RMD Open (free to access) here. To speak to us about our research and commitment to scientific integrity, email enquiries@maverex.com.